Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 23 unusual trades.
Delving into the details, we found 56% of traders were bullish, while 26% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $401,684, and 14 were calls, valued at $675,514.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $200.0 for Novo Nordisk over the recent three months.
Volume & Open Interest Development
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $70.0 to $200.0 over the preceding 30 days.
Novo Nordisk Option Activity Analysis: Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
| NVO | CALL | SWEEP | BULLISH | 01/17/25 | $2.28 | $2.19 | $2.25 | $125.00 | $112.3K | 6.6K | 702 |
| NVO | PUT | SWEEP | BULLISH | 03/21/25 | $10.7 | $10.65 | $10.65 | $115.00 | $93.7K | 1.1K | 100 |
| NVO | CALL | TRADE | BULLISH | 01/17/25 | $13.65 | $13.5 | $13.6 | $100.00 | $85.6K | 1.1K | 78 |
| NVO | PUT | TRADE | BULLISH | 03/21/25 | $36.25 | $35.95 | $35.95 | $145.00 | $71.9K | 11 | 20 |
| NVO | CALL | SWEEP | BULLISH | 12/20/24 | $2.37 | $2.26 | $2.37 | $120.00 | $70.6K | 9.7K | 632 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Current Position of Novo Nordisk
- With a trading volume of 3,829,487, the price of NVO is up by 1.72%, reaching $109.05.
- Current RSI values indicate that the stock is may be approaching oversold.
- Next earnings report is scheduled for 79 days from now.
What The Experts Say On Novo Nordisk
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $158.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.* An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160. * An analyst from BMO Capital has decided to maintain their Outperform rating on Novo Nordisk, which currently sits at a price target of $156.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with Benzinga Pro for real-time alerts.
金融巨头对诺和诺德采取了明显的看涨举动。我们对诺和诺德（纽约证券交易所代码：NVO）期权历史的分析显示了23笔不寻常的交易。
深入研究细节，我们发现56％的交易者看涨，而26％的交易者表现出看跌倾向。在我们发现的所有交易中，有9笔是看跌期权，价值为401,684美元，14笔是看涨期权，价值675,514美元。
预测的价格区间
根据交易活动，看来重要投资者的目标是在最近三个月中将诺和诺德的价格范围从70.0美元扩大到200.0美元。
交易量和未平仓合约的发展
评估交易量和未平仓合约是期权交易的战略步骤。这些指标揭示了Novo Nordisk在指定行使价下期权的流动性和投资者对Novo Nordisk期权的兴趣。即将发布的数据可视化了与诺和诺德的大量交易相关的看涨期权和未平仓合约的波动，在过去30天内，行使价范围从70.0美元到200.0美元不等。
诺和诺德期权活动分析：过去 30 天
观察到的最大期权交易：
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
NVO | CALL | SWEEP | BULLISH | 01/17/25 | $2.28 | $2.19 | $2.25 | $125.00 | $112.3K | 6.6K | 702 |
NVO | PUT | SWEEP | BULLISH | 03/21/25 | $10.7 | $10.65 | $10.65 | $115.00 | $93.7K | 1.1K | 100 |
NVO | CALL | TRADE | BULLISH | 01/17/25 | $13.65 | $13.5 | $13.6 | $100.00 | $85.6K | 1.1K | 78 |
NVO | PUT | TRADE | BULLISH | 03/21/25 | $36.25 | $35.95 | $35.95 | $145.00 | $71.9K | 11 | 20 |
NVO | CALL | SWEEP | BULLISH | 12/20/24 | $2.37 | $2.26 | $2.37 | $120.00 | $70.6K | 9.7K | 632 |
关于 Novo Nordisk
诺和诺德拥有全球品牌糖尿病治疗市场约三分之一的份额，是全球领先的糖尿病护理产品提供商。该公司总部位于丹麦，生产和销售各种人用和现代胰岛素、注射型糖尿病治疗药物（如 GLP-1 疗法）、口服抗糖尿病药物和肥胖疗法。Novo还有一个生物制药板块（约占收入的10％），专门研究血友病和其他疾病的蛋白质疗法。
在研究了Novo Nordisk的期权交易模式之后，我们的注意力现在直接转向了该公司。这种转变使我们能够深入研究其目前的市场地位和表现
诺和诺德的当前位置
专家对诺和诺德的看法
在过去的30天中，共有2位专业分析师对该股发表了看法，将平均目标股价设定为158.0美元。
检测到不寻常的期权活动：智能货币在移动
Benzinga Edge的不寻常期权委员会在潜在的市场推动者发生之前就发现了它们。看看大笔资金对你最喜欢的股票持有哪些头寸。点击此处查看。* 坎托·菲茨杰拉德的一位分析师将其股票评级下调至增持，目标股价为160美元。*BMO Capital的一位分析师已决定维持对诺和诺德的跑赢大盘评级，该评级目前的目标股价为156美元。
交易期权涉及更大的风险，但也提供了更高利润的潜力。精明的交易者通过持续的教育、战略贸易调整、利用各种指标以及随时关注市场动态来降低这些风险。使用 Benzinga Pro 了解诺和诺德的最新期权交易，获取实时提醒。
